Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Houttuynoid A in medicine for preventing and treating liver injury

A technology of liver damage and medicine, which is applied in the prevention and treatment of liver damage. As a medicine, Houttuynoid A can solve the problems of liver damage, aggravation, and elevation, and achieve the effect of highlighting the substantial characteristics and strong therapeutic effect

Inactive Publication Date: 2013-01-09
艾韦特(溧阳)医药科技有限公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

4. Other reasons: primary and secondary liver tumors, liver congestion caused by cardiac insufficiency, certain congenital liver diseases, high-priced intravenous nutrition, etc., can all cause liver damage to varying degrees. The early manifestations of these liver damage are often Elevation of ALT (transaminase) or bilirubin, if the cause is not eliminated, the liver damage will be further aggravated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Houttuynoid A in medicine for preventing and treating liver injury
  • Application of Houttuynoid A in medicine for preventing and treating liver injury
  • Application of Houttuynoid A in medicine for preventing and treating liver injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Embodiment 1: the preparation of compound Houttuynoid A tablet involved in the present invention:

[0012] Take 20 grams of compound Houttuynoid A, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tabletting machine.

Embodiment 2

[0013] Embodiment 2: the preparation of compound Houttuynoid A capsule involved in the present invention:

[0014] Get 20 grams of compound Houttuynoid A, add conventional auxiliary materials such as starch 180 grams for preparing capsules, mix well, and pack into capsules to make 1000 tablets.

[0015] The following pharmacodynamic experiments will further illustrate its drug activity.

[0016] The following are some pharmacological experimental data:

experiment example 1

[0017] Experimental example 1. The effect of Houttuynoid A on preventing and treating liver injury

[0018] (1) Protective effect of Houttuynoid A on D-galactosamine (D-GalN)-induced acute liver injury in mice

[0019] The mice were divided into 5 groups, and the control group was intragastrically administered with normal saline (0.3 mLd -1 ), for 7 days in a row, on the 7th day intraperitoneal injection of normal saline (0.15mL10g -1 ); D-GalN, Houttuynoid A (1.5, 3.0, 6.0 mgkg -1 ) Each group was administered with normal saline and different concentrations of Houttuynoid A (0.3 mLd -1 ), for 7 consecutive days, on the 7th day intraperitoneal injection of D-GalN (800mgkg -1 , 0.15mL10g -1 ), blood was collected after 16 hours, and AST and ALT activities were measured.

[0020] Table 1 Protective effect of Houttuynoid A on acute liver injury induced by D-GalN

[0021]

[0022] Note: 1) p2) p<0.01 vs D-GalN group

[0023] It can be seen from Table 1 that Houttuynoid...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The inventor discovers that Houttuynoid A has a prevention effect on mice acute liver injury induced by D-galactosamine (D-GalN) and has a prevention effect on mice acute liver injury induced by carbon tetrachloride (CCl4) through a pharmacological study. Therefore, Houttuynoid A can be utilized to prepare the medicines for preventing and treating liver injury or hepatitis. Application of Houttuynoid A on preparation of the medicine for preventing and treating liver injury provided by the invention is disclosed firstly. The skeleton type belongs to new skeleton type, and the activity of Houttuynoid A on the treatment effect of liver injury is unexpectedly strong; and the probability that any revelation is provided by other compounds does not exist, Houttuynoid A has the excellent substantive features, and Houttuynoid A obviously has a remarkable progress when being used for preventing liver injury.

Description

technical field [0001] The present invention relates to Houttuynoid A, in particular relates to Houttuynoid A used as medicine for preventing and treating liver damage. technical background [0002] There are multiple reasons for causing liver damage: 1. Viral infection: caused by a variety of hepatitis viruses, with strong infectivity, complex transmission routes, wide epidemic range, and high incidence rate. 2. Drugs or chemical poisons: Many drugs and chemical poisons can cause liver damage, drug-induced hepatitis or toxic hepatitis. 3. Alcoholism: Alcohol damages the liver very seriously. The consequences of the damage include alcoholic hepatitis, alcoholic fatty liver, and alcoholic cirrhosis, mainly due to the toxicity of alcohol (ethanol) and its metabolite acetaldehyde on liver cells. caused by direct damage. 4. Other reasons: primary and secondary liver tumors, liver congestion caused by cardiac insufficiency, certain congenital liver diseases, high-priced intrave...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P1/16
Inventor 蒋鹤松黄晨吴俊华
Owner 艾韦特(溧阳)医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com